STOCK ANALYSIS  ·  NSE: INDSWFTLAB

A complete analysis after the Q2 FY27 results: what changed, what the price already assumes, and what could still go wrong, with worked examples you can repeat on a calculator.

11 November 2026

IN THIS ANALYSIS

Tap any line to jump straight to it.

I   The stock at a glance

II   Where the business came from

III   Reading the Q2 FY27 numbers

IV   The export engine: brands over contracts

V   The run-rate test

VI   What the price already assumes

VII   The risks worth respecting

VIII   Three ways investors approach it

IX   Your watch-list for the next results

X   The bottom line

Few small-cap pharma stories in India have rewritten themselves as quickly as Ind-Swift Laboratories. Within the last twelve months the shares have traded anywhere between about ₹87 and ₹425. In that stretch the company reported two standout quarters, put global formulation partnerships into operation, and told the market it expects to cross ₹900 crore in revenue this financial year.

The question every investor is now asking is simple: is this a re-rating with room left to run, or a rally that has already priced in the good news? This analysis takes the numbers one at a time, with examples you can reproduce yourself, so you can answer that question with evidence rather than excitement.

Unless stated otherwise, figures are on a standalone basis for the quarter ended 30 September 2026, and market data is as of late October 2026.

I
The stock at a glance
◆

Company Ind-Swift Laboratories Ltd

Core business Finished dosage formulations

Q2 FY27 operating income ₹234.89 crore

Q2 FY27 operating EBITDA ₹42.33 crore

Operating EBITDA margin 18.02%

Q2 FY27 profit after tax ₹31.03 crore

Market capitalisation (26 Oct 2026) about ₹2,931 crore

12-month price range ₹87 to about ₹425

Balance sheet, per management Net-debt-free

FY27 revenue guidance ₹900 crore, 18%+ margin

Read these ten lines as a story rather than a scoreboard. A company that makes 18 paise of operating profit on every rupee of sales, owes almost nothing, and is guiding for a step-change in revenue is a very different animal from the loss-making, debt-laden business it was only a few years ago. The rest of this analysis tests whether that story holds up.

↑  BACK TO CONTENTS

II
Where the business came from
◆

Ind-Swift Laboratories was incorporated in 1995 and for most of its life it was the active pharmaceutical ingredient (API) and contract research and manufacturing arm of the wider Ind-Swift group. Through FY24 that was the identity: make the chemical building blocks that other companies turn into medicines.

Then the strategy changed. The group sold its API business, used the proceeds to repay external debt, and brought its formulations operations into the listed company. Today Ind-Swift describes itself as a focused finished dosage formulation (FDF) manufacturer, which means it makes the tablets, capsules and other products that patients actually take.

A SIMPLE WAY TO SEE WHY THIS MATTERS

Think of an API as flour and a formulation as branded bread. Flour is sold on price, margins are thin, and the buyer can switch suppliers easily. Bread sold under a registered brand, in a market where you hold the licence, carries pricing power and repeat demand. When a company moves from flour to bread, the same factory can earn a much higher margin. That is precisely what the margin line below shows.

↑  BACK TO CONTENTS

III
Reading the Q2 FY27 numbers
◆

Ind-Swift announced its September-quarter results on 29 and 30 October 2026. Set against the same quarter a year earlier, the changes are large enough to deserve a line-by-line look.

Operating income ₹156.43 cr  →  ₹234.89 cr

Operating EBITDA ₹8.55 cr  →  ₹42.33 cr

Operating EBITDA margin 5.46%  →  18.02%

Profit after tax ₹8.76 cr  →  ₹31.03 cr

Finance cost down 33.83% to ₹1.33 cr

WORKED EXAMPLE · OPERATING LEVERAGE

Revenue grew by ₹78.46 crore year on year (₹234.89 crore minus ₹156.43 crore). Operating EBITDA grew by ₹33.78 crore (₹42.33 crore minus ₹8.55 crore). Divide the second number by the first and you get roughly 43%. In plain words, of every extra rupee of sales this quarter, about 43 paise dropped straight through to operating profit. That is far higher than the 18% average margin, and it is the signature of a business where fixed costs are already covered and new volume is almost pure contribution.

WORKED EXAMPLE · SEQUENTIAL MOMENTUM

Q1 FY27 operating income was ₹186.08 crore. Q2 was ₹234.89 crore. That is a 26% jump in a single quarter, achieved while the operating EBITDA margin held steady (17.91% in Q1, 18.02% in Q2). Growth without margin dilution is the combination investors look for, because it says volume is not being bought with discounts.

HALF-YEAR VIEW

Adding the two quarters gives H1 FY27 operating income of about ₹421 crore and operating EBITDA of about ₹75.6 crore. Reported H1 income growth was 35.79%, lower than Q2 alone, which tells you the acceleration is recent and the second half starts from a higher base.

A NOTE ON READING DATA

Different data providers sometimes show slightly different figures for the same quarter because some quote standalone numbers and others consolidated. Consolidated Q2 net profit, for example, was reported at about ₹34.2 crore against ₹31.03 crore standalone. Always match like with like before comparing.

Research is only half the job. Putting it to work without brokerage eating the return is the other half, and that is where Brokerage Free Investments comes in.

↑  BACK TO CONTENTS

IV
The export engine: brands over contracts
◆

In Q2 FY27, 69.09% of export sales came from Ind-Swift’s own brands and 30.91% from contract manufacturing. Europe was the largest contributor to both, at 29.50% of export sales through own brands and 22.83% through contract manufacturing.

Own-brand revenue is the better kind. The company controls the price, the customer relationship and the registration, instead of depending on another company’s order book.

REGISTRATIONS, EXPLAINED

A product registration is permission to sell a specific medicine in a specific country. Ind-Swift now reports more than 900 global registrations, up from more than 750 previously, and expects around 333 more during 2026-27. Picture each registration as a shop licence in a new town. A company with 900 licences has 900 places to sell; every additional one adds to a base that does not need to be rebuilt each year.

Alongside its own brands, the company has put formulation and contract development partnerships into operation with global pharmaceutical groups, reported to include Viatris, Manx and Arrotex. These give the factory steady, planned volumes and lend credibility with regulators, though they also create a dependency that we address in the risk section.

↑  BACK TO CONTENTS

V
The run-rate test
◆

Management has guided for standalone revenue of ₹900 crore in FY27 with EBITDA margins above 18%, and for ₹1,500 crore of revenue and ₹200 crore of profit after tax by FY30. Guidance is only useful if you can test it against what has already happened. Here is how.

WORKED EXAMPLE · CAN FY27 HAPPEN?

Target revenue for FY27 ₹900 cr

Delivered in H1 ₹421 cr

Needed in H2 ₹479 cr

Needed per quarter about ₹240 cr

Q2 actual ₹235 cr

The second half therefore needs each quarter to come in about 2% above what Q2 just delivered. That is not a stretch, provided Q2 was a genuine run-rate and not a one-off. The same logic works for profit: at 18% on ₹900 crore, full-year operating EBITDA would be about ₹162 crore. H1 delivered about ₹75.6 crore, so H2 needs about ₹86 crore, roughly ₹43 crore a quarter against ₹42.33 crore in Q2.

WORKED EXAMPLE · THE FY30 PROFIT AMBITION

H1 FY27 profit after tax was about ₹55.7 crore (₹24.68 crore plus ₹31.03 crore). Doubled, that is an annualised pace of roughly ₹111 crore. The FY30 goal of ₹200 crore asks for that pace to nearly double again over three-plus years. Ambitious, but a long way from fantasy when revenue is already compounding at this speed.

↑  BACK TO CONTENTS

VI
What the price already assumes
◆

A great business can still be a poor purchase if the price is too high. So the useful question is not “is the company good?” but “what must go right for today’s price to earn me a return?”

On 26 October 2026, before the Q2 results, the market capitalisation was about ₹2,931 crore. Against the annualised H1 profit of roughly ₹111 crore, that is about 26 times earnings. Published trailing multiples vary by provider because the earnings base has been changing so fast, which is itself a sign of how quickly the company is moving.

WORKED EXAMPLE · WHAT YOU MUST BELIEVE

Assume the FY30 profit goal of ₹200 crore is delivered, and the market values the company at three different multiples at that time, roughly 3.4 years from now. Compare the resulting value with ₹2,931 crore:

At 15× earnings (₹3,000 cr) about 0.7% a year

At 20× earnings (₹4,000 cr) about 9.6% a year

At 25× earnings (₹5,000 cr) about 17% a year

This is illustrative arithmetic, not a forecast, and it ignores dividends and any new shares issued. The lesson is the sensitivity. If the targets are met but the market pays only 15 times earnings, a buyer at the late-October price earns almost nothing. If the market pays 25 times, the return is excellent. Your outcome depends as much on the multiple the market is willing to pay as on the profit the company delivers.

Before applying this, check the live share price. Every move in price changes the sums above, and the shares have been volatile: they fell roughly 19% in the month to 26 October after a sharp run-up, and had jumped about 18% in a single session when Q1 results came out in August.

↑  BACK TO CONTENTS

VII
The risks worth respecting
◆

Execution. Guidance of ₹900 crore this year and ₹1,500 crore by FY30 is bold. A single weak quarter can turn confidence into disappointment, and small-cap prices react harder than large-cap ones.

Valuation and volatility. The shares rose more than threefold from their 12-month low. Stocks that have moved that far can fall quickly, and the 19% monthly pullback is a reminder.

Regulatory timing. Rollout depends on facility approvals and dossier registrations in many countries. Delays are common in pharma and rarely announced in advance.

Partner dependence. Contract and CDMO volumes rely on a handful of global partners. Losing or delaying one would be visible in the numbers.

Share count. Warrant conversions, such as the 14,00,000 shares the promoter-linked investor Essix Biosciences took up on 8 October 2026, raise promoter holding, which is a positive signal, but they also add to the number of shares over which profit is divided.

Clean-up already done. On the positive side, an arbitration with PI Industries ended in April 2026 with all claims rejected and no financial impact on the company, removing one legal overhang.

↑  BACK TO CONTENTS

VIII
Three ways investors approach it
◆

The staged buyer. Instead of committing everything at once, this investor splits ₹1,00,000 into four tranches of ₹25,000 spread across the next two results seasons. If the stock falls, later tranches buy cheaper. If it rises, the first tranche is already working. It trades some upside for a lot of peace of mind.

The results tracker. This investor waits for each quarterly update and acts only if the key signals in the next section hold. Waiting costs some of the move, but avoids buying on hope.

The patient holder. This investor accepts volatility, owns a modest position sized so a 30% drop would not hurt, and measures progress against the FY30 goals rather than the daily chart.

WORKED EXAMPLE · WHY TRADING COSTS MATTER

Suppose, purely as an illustration, that a broker charges 0.3% on each side of a trade. A staged buyer who invests ₹1,00,000 and later sells it all pays about ₹300 on the way in and ₹300 on the way out, or ₹600, which is 0.6% of the capital. In the 9.6% a year scenario above, that is a meaningful slice of the return, and the more often you add to a position, the more it compounds against you.

This is why many investors choose to trade through Brokerage Free Investments. Check the current terms there and see whether it suits the way you invest.

↑  BACK TO CONTENTS

IX
Your watch-list for the next results
◆

One. Margin. Does operating EBITDA margin stay at or above 18%? A dip below 16% would suggest Q2 benefited from timing.

Two. Revenue pace. Is quarterly operating income holding near or above ₹240 crore? That is the pace the ₹900 crore guidance needs.

Three. Registrations. Is the count moving from 900 toward the targeted 333 additions? This is the best leading indicator of future export revenue.

Four. Balance sheet. Does the company remain net-debt-free while spending on capacity? Growth funded by debt would change the quality of the story.

Five. Ownership. Are promoter and institutional holdings stable or rising? Foreign institutional holding was 10.78% at the end of September 2026, up slightly from the previous quarter.

↑  BACK TO CONTENTS

X
The bottom line
◆

Ind-Swift Laboratories has shown what a genuine business transformation looks like in the numbers: revenue up 50%, operating profit up almost fivefold, margins that tripled, interest costs falling and a balance sheet largely free of net debt. The guidance appears achievable if Q2 proves to be the new normal.

The harder question is price. At late-October levels, much of the good news is already reflected, and your return from here depends on whether the company hits its targets and whether the market keeps paying a premium multiple for them. That is why the next two quarterly results matter more than any headline.

Whatever you decide, decide with the numbers in front of you, and keep your costs low so more of the return stays yours.

Ready to invest with confidence?

Open your account with Brokerage Free Investments and put this research to work on your terms.

VISIT BROKERAGE FREE INVESTMENTS  →

Important: this article is for education and information only. It is not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks. Figures are drawn from company disclosures and market data and may change; please verify against the latest exchange filings and consult a SEBI-registered adviser before investing.

↑  BACK TO CONTENTS